NDA 021150/S-021

SUPPLEMENT APPROVAL

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Attention: Joseph R. Coskey, M.S., RAC
Associate Manager, Regulatory Affairs
7050 Camp Hill Road
Mail Stop III
Fort Washington, PA 19034-2299

Dear Mr. Coskey:

Please refer to your supplemental new drug application (sNDA) dated and received on May 4, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg) extended-release tablets.

This "Prior Approval" supplemental new drug application provides for revised carton labeling, specifically the Principal Display Panel, to help to clarify for consumers the purpose of the active ingredient, pseudoephedrine HCl, in Zyrtec-D extended-release tablets.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling, described in the table below and must be in the "Drug Facts" format (21 CFR 201.66), where applicable. Also submit the current immediate container labeling (6-count blister) with the FPL for a complete record of this product.

Submitted Draft Labeling	Date Submitted
Zyrtec-D 12-count carton	October 20, 2021
Zyrtec-D 24-count carton	October 20, 2021

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.[1] For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 021150/S-021**." Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.[2] Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

[1] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

[2] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

If you have any questions, contact Xiaoxue Nehrbass, Regulatory Project Manager, at Xiaoxue.Nehrbass@fda.hhs.gov or (301) 796-1486.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Acting Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
11/03/2021 01:54:41 PM